Partnership brings new AI model promising faster drug discovery
Insilico Medicine and Liquid AI released LFM2-2.6B-MMAI, a 2.6‑billion‑parameter, lightweight AI model built to handle multiple drug‑discovery tasks while running on private company servers. The model claims performance comparable to much larger systems and is being pitched to speed discovery for aging‑related diseases such as fibrosis and neurodegeneration while keeping proprietary molecular and clinical data on‑premise.
Why it mattersThe 2.6 billion-parameter, on-premise model keeps proprietary molecular data private, lowering regulatory and IP risk for in-house drug discovery.
People Mentioned
Kyle Umipig